CRST – Clinical trials with over 25 years of experience
CRST and Kancera AB entered into a contract for a First-in-human trial of KAND145, Kancera’s second generation fractalkine blocking drug candidate, primarily intended for cancer indications.
Petri has over 30 years of experience in clinical pharmacology both in academy and in biopharma industry. We warmly welcome Petri into the CRST -team!
Professor Juha Rinne, a leading expert from the scientific team of CRST contributed in this study.
Professori Markku Koulu ja Painoklinikan perustaja André Heikius kertoivat aiheesta CRST:n seminaarissa.
CRST’s Key Account Manager Nikhil Ahuja tells more about his work at CRST.
CRST Oy ja suomalainen lääkekehitysyhtiö Herantis Pharma Oyj allekirjoittivat merkittävän kliinisen tutkimushankkeen toteutukseen liittyvän sopimuksen.
Alzinova AB, a Swedish biopharma company announced that the last patient in the Phase 1b study with the vaccine candidate ALZ-101 against Alzheimer’s disease has been enrolled and received his first dose.
Kumppanuus on tehnyt mahdolliseksi yhdistää PET -keskuksen kuvantamisinstrumentit kummankin keskuksen erikoisosaamiseen ja asiantuntijuuteen.
Video – CEO Antti Vuolanto from Herantis Pharma describes the collaboration with CRST
In addition to conference participation, Ville Ranta-Panula, CRST’s Chief Commercial Officer, had a chance to meet several clients In San Francisco and in New York City.
The first-in-human Phase 1 clinical trial of Avilex Pharma’s lead candidate AVLX-144 was conducted successfully in collaboration with CRST.
Together we organized public event, where our experts gave lectures about memory and brain diseases.
CRST is arranging a crowdfunding share emission together with Invesdor Nordics From its inception as a company, CRST has been aiming to grow profitably. After
CRST’s CSO Mika Scheinin was nominated as the Clinical Investigator of the Year 2022 CRST’s CSO Mika Scheinin was nominated as the Investigator of the